Warfarin Dosing: Do Genotype-Based Algorithms Improve Outcomes?

MedicalResearch.com Interview with:
David Ldr_david_l_brown. Brown, MD, FACC
Professor of Medicine
Cardiovascular Division
Washington University School of Medicine
St. Louis, MO 63110

MedicalResearch: What are the main findings of the study?

Dr. Brown: This meta-analysis of randomized controlled trials showed that using a genotype-based warfarin dosing algorithm did not improve the process or outcomes of anticoagulation compared to using a clinical dosing algorithm.

MedicalResearch: Were any of the findings unexpected?

Dr. Brown: The findings may be surprising to many clinicians and investigators since the genotypes used to adjust warfarin dosing in the included studies are responsible for approximately one-third of the variation in dose requirement among patients taking warfarin.

MedicalResearch: What should clinicians and patients take away from your report?

Dr. Brown: They should take away that although personalized medicine is an attractive concept, its implementation requires proof of patient benefit just like another new test, drug or procedure.

MedicalResearch: What recommendations do you have for future research as a result of this study? 

Dr. Brown: As new genetic polymorphisms are discovered and new algorithms are developed, they will need to be tested in appropriately sized trials to demonstrate clinical benefit.


Last Updated on June 18, 2014 by Marie Benz MD FAAD